About Contact Us Careers

Pancreatic Adenocarcinoma Treatment Market Size and Forecast, by Type (Chemotherapy, Targeted Therapy), Affected Area (Exocrine, Endocrine) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 3373
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Pancreatic Adenocarcinoma Treatment Market Outlook:

Pancreatic Adenocarcinoma Treatment Market size was over USD 2.92 billion in 2025 and is projected to reach USD 11.11 billion by 2035, witnessing around 14.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of pancreatic adenocarcinoma treatment is assessed at USD 3.3 billion.

Pancreatic Adenocarcinoma Treatment
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The market growth is driven by rising prevalence of pancreatic adenocarcinoma among people across the world. The changing lifestyle habits and adoption of alcohol are estimated to boost the market demand. Moreover, increasing prevalence of obesity will impel the market revenue. As of 2022 reports, more than 1 billion population across the globe are suffering from obesity with over 600 million adults, 40 million children, and more than 300 million adolescents.

Additionally, poor diet and unhealthy lifestyle practices are fueling the market growth. Furthermore, increasing demand for packed foods and beverages across the globe will propel the market size. The lack of therapeutic procedures and early diagnostic tests for pancreatic adenocarcinoma is also estimated to create opportunities for the market expansion.

Key Pancreatic Adenocarcinoma Treatment Market Insights Summary:

  • Regional Insights:

    • The North America pancreatic adenocarcinoma treatment market is projected to secure over 33% share by 2035, underpinned by rising pancreatic adenocarcinoma prevalence across the region.
    • The European market is anticipated to hold nearly 26% share by 2035, supported by high alcohol consumption across the region.

  • Segment Insights:

    • The chemotherapy segment in the Pancreatic Adenocarcinoma Treatment Market is expected to capture about 40% share by 2035, propelled by the escalating number of patients requiring chemotherapy.
    • The exocrine segment is set to command roughly 56% share by 2035, owing to the increasing prevalence of exocrine cancers.

  • Key Growth Trends:

    • Increasing Prevalence of Pancreatic Disorders owing to Germline Mutations
    • Rising Geriatric Population across the World with Reduced Immunity

  • Major Challenges:

    • Rising Cost of Drug Development and Treatment
    • Side Effects of Radiation and Chemotherapy

  • Key Players: Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation.

Global Pancreatic Adenocarcinoma Treatment Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 2.92 billion
    • 2026 Market Size: USD 3.3 billion
    • Projected Market Size: USD 11.11 billion by 2035
    • Growth Forecasts: 14.3%

  • Key Regional Dynamics:

    • Largest Region: North America (33% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: – United States, China, Germany, Japan, United Kingdom
    • Emerging Countries: – India, South Korea, Brazil, Australia, Canada

    • Last updated on : 19 November, 2025

Growth Drivers

  • Increasing Prevalence of Pancreatic Disorders owing to Germline Mutations – In the U.S. more than 60,000 people are diagnosed with pancreatic cancer as of 2023.
  • Rising Geriatric Population across the World with Reduced Immunity – As per the estimations in 2023, more than 1 in 6 people in America which is 80 million people are now the age 65 and above.
  • Increasing Incidence of Cancers related to the Digestive System and Stomach owing to Unhealthy Foods – The number of cancer cases reported in the year 2019 across the U.S. was over 1,752,700 and 600,000 people died from cancer.
  • Increasing use of Chemotherapy and Radiotherapy Treatments around the Globe – More than 50% of cancer patients are estimated to receive radiation therapy as of 2023 estimations.
  • Rising Healthcare Expenditure with Improved Infrastructure Facilities – The healthcare expenditure of the U.S.  was estimated to increase by more than 25% in the year 2021 with a value of over USD 4 trillion.

Challenges

  • Rising Cost of Drug Development and Treatment
  • Side Effects of Radiation and Chemotherapy –

The side effects of chemotherapy include pain, dizziness, fever, vomiting, and frequent bowel movement and the side effects of radiation therapy include diarrhea, shortness of breath, change in taste, and urinary and bladder problems. All these factors are estimated to be the reason for the hampering of market growth.

  • Stringent Government Regulatory Guidelines

Pancreatic Adenocarcinoma Treatment Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

14.3%

Base Year Market Size (2025)

USD 2.92 billion

Forecast Year Market Size (2035)

USD 11.11 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, South Korea, Malaysia, Australia, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Pancreatic Adenocarcinoma Treatment Market Segmentation:

Type Segment Analysis

The chemotherapy segment is estimated to gain largest market share of about 40% by 2035. The segment growth can be attributed to increasing number of patients in the need of chemotherapy. Chemotherapy is the first line of treatment in cancer disorders along with medications. More than 26% of people across the UK are estimated to have chemotherapy as the primary treatment for pancreatic cancer as of 2020.

The increasing use of chemotherapy and targeted therapy for cancer cell isolation in tumor formation will propel the market expansion. Further, the increasing presence of competent practitioners and increasing medical facilities across the world are expected to drive segment growth. Moreover, the growing number of hospitals and clinics that provide chemotherapy with advanced equipment and decent infrastructure will fuel the segment revenue.

Affected Area Segment Analysis

The exocrine segment is predicted to account for around 56% share by 2035. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body. The segment growth is attributed to increasing prevalence of exocrine cancers. More than 90% of pancreatic cancers across the world are exocrine tumors as of estimations in 2022. Cancer in the ducts affects the exocrine cells of the pancreas causing exocrine cancer. High awareness and technological advancements in endocrine cancer diagnostics or tumor diagnosis among people will boost the segment growth. The increasing privatization across the world and an increasing number of hospitals with chemotherapy and radiology treatment will fuel the market revenue.

Our in-depth analysis of the global market includes the following segments:

By Type
  • Chemotherapy
  • Targeted Therapy
  • Others

 

By Affected Area
  • Exocrine
  • Endocrine
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Pancreatic Adenocarcinoma Treatment Market - Regional Analysis

North American Market Insights

The pancreatic adenocarcinoma treatment market share in North America is anticipated to exceed 33% by 2035. The market domination is driven by increasing prevalence of pancreatic adenocarcinoma disease across the region. The increasing population across the region along with the changing food habits will propel the market size. The growing cancer rate across the region with a high number of patients under treatment will fuel the market growth. Also, the increased number of key players in the region interested in investment in the healthcare sector is estimated to hike the market growth across the region.

The presence of a large population suffering from the disease and increasing acceptance of pancreatic treatment procedures in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States were evaluated to suffer from pancreatic cancer. The total number of cases is predicted to rise by 3.2 percent since the previous year. In addition, the strong presence of major market players is also expected to expand the region's market in the upcoming years. Moreover, rising occurrence of pancreatic adenocarcinoma and the growing establishment of critical care centers in the region will fuel the market expansion.

Europe Market Insights

The European pancreatic adenocarcinoma treatment market is estimated to hold 26% share by the end of 2035, propelled by high consumption of alcohol and beverages across the region. Increasing research and development activities across the region for the invention in the discovery of new treatment procedures and drug therapies will hike the market revenue. The market growth is also attributed to the increasing number of people who smoke cigarettes across the region.

The growing number of people with obesity rates in the region will boost the market growth. The gastrointestinal problems and digestive issues in people owing to the high consumption of cheese and other sugary products will fuel the market size. The presence of many key players across the region who are investing in the research and development of diagnostic tests will have a positive impact on the market revenue. The presence of a very simple approval process for the new clinical trial drugs and treatment procedures in the region is also expected to drive the market growth.

APAC Market Insights

The Asia Pacific market is predicted to register significant CAGR till 2035, due to well-established clinics in the region. The number of people suffering from pancreatic adenocarcinoma disease will propel the market revenue. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is also driving the market growth.

The growing healthcare expenditure across the region to prevent the incidence of cancer will fuel the market growth. The rising pharmaceutical companies across the region with clinical trials to develop new drugs will hike the market revenue. The rising number of clinical care centers and hospitals with facilities for targeted therapy, chemotherapy, and radiotherapy is estimated to propel the market size. The increasing government initiatives to increase awareness among people regarding diagnostic awareness are driving the market growth across the region.

Pancreatic Adenocarcinoma Treatment Market growth
Get Strategic Analysis by Region Now: Request Free Sample PDF

Pancreatic Adenocarcinoma Treatment Market Players:

    • Amgen Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffman-La Roche AG
    • Novartis AG
    • Pfizer Inc.
    • Aduro Biotech Inc.
    • Clovis Oncology Inc.
    • Threshold Pharmaceuticals Inc.
    • NewLink Genetics Corp
    • Infinity Pharmaceuticals Inc.
    • Celgene Corporation

Recent Developments

  • Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.

  • Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation (ODD) along with standard chemotherapy care for the treatment of pancreatic cancer.

  • Report ID: 3373
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT
  • Explore a preview of key market trends and insights
  • Review sample data tables and segment breakdowns
  • Experience the quality of our visual data representations
  • Evaluate our report structure and research methodology
  • Get a glimpse of competitive landscape analysis
  • Understand how regional forecasts are presented
  • Assess the depth of company profiling and benchmarking
  • Preview how actionable insights can support your strategy

Explore real data and analysis

Download Free Sample Report

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of pancreatic adenocarcinoma treatment is assessed at USD 3.3 billion.

The global pancreatic adenocarcinoma treatment market size surpassed USD 2.92 billion in 2025 and is projected to witness a CAGR of over 14.3%, crossing USD 11.11 billion revenue by 2035.

The North America pancreatic adenocarcinoma treatment market is projected to secure over 33% share by 2035, underpinned by rising pancreatic adenocarcinoma prevalence across the region.

Key players in the market include Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation.

Pancreatic Adenocarcinoma Treatment Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos